MediciNova to Participate in the B. Riley Neuroscience Conference
April 19 2021 - 6:30AM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number: 4875), today announced that Yuichi
Iwaki, MD, PhD, President and Chief Executive Officer,
and Geoffrey O'Brien, JD/MBA, Vice President and Executive
Officer, will participate in a fireside chat, hosted by B. Riley
Analyst Mayank Mamtani, regarding MediciNova’s development of
MN-166 (ibudilast) for neurological conditions at the virtual B.
Riley Neuroscience Conference on Thursday, April 29, 2021 at 1:30
p.m. ET. MediciNova will be available for one-on-one
meetings at this conference and investors may request a one-on-one
meeting through B. Riley.
About MN-166 (ibudilast)
MN-166 (ibudilast) is a first-in-class, orally
bioavailable, small molecule macrophage migration inhibitory factor
(MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor
that suppresses pro-inflammatory cytokines and promotes
neurotrophic factors. Our earlier human studies demonstrated
significant reductions of serum MIF level after treatment with
MN-166 (ibudilast). It also attenuates activated glial cells, which
play a major role in certain neurological conditions. MN-166
(ibudilast)'s anti-neuroinflammatory and neuroprotective actions
have been demonstrated in preclinical and clinical studies, which
provide the rationale for treatment of amyotrophic lateral
sclerosis (ALS), progressive multiple sclerosis (MS) and other
neurological diseases such as glioblastoma (GBM), and substance
abuse/addiction. MediciNova is developing MN-166 for ALS,
progressive MS, and other neurological conditions such as
degenerative cervical myelopathy (DCM), glioblastoma, substance
abuse/addiction, and chemotherapy-induced peripheral neuropathy, as
well as prevention of acute respiratory distress syndrome (ARDS)
caused by COVID-19. MediciNova has a portfolio of patents which
covers the use of MN-166 (ibudilast) to treat various diseases
including ALS, progressive MS, and drug addiction.
About
MediciNova
MediciNova, Inc. is a publicly-traded
biopharmaceutical company founded upon developing novel,
small-molecule therapeutics for the treatment of diseases with
unmet medical needs with a primary commercial focus on the U.S.
market. MediciNova's current strategy is to focus on MN-166
(ibudilast) for neurological disorders such as progressive multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative
cervical myelopathy (DCM), substance dependence (e.g., alcohol use
disorder, methamphetamine dependence, opioid dependence) and
glioblastoma (GBM), as well as prevention of acute respiratory
distress syndrome (ARDS) caused by COVID-19, and MN-001
(tipelukast) for fibrotic diseases such as nonalcoholic
steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
MediciNova’s pipeline also includes MN-221 (bedoradrine) and MN-029
(denibulin). For more information on MediciNova, Inc., please visit
www.medicinova.com.
Statements in this press release that are not
historical in nature constitute forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, without limitation, statements regarding the future
development and efficacy of MN-166, MN-001, MN-221, and MN-029.
These forward-looking statements may be preceded by, followed by or
otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will,"
"would," “considering,” “planning” or similar expressions. These
forward-looking statements involve a number of risks and
uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these
forward-looking statements include, but are not limited to, risks
of obtaining future partner or grant funding for development of
MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient
capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties
inherent in clinical trials, including the potential cost, expected
timing and risks associated with clinical trials designed to meet
FDA guidance and the viability of further development considering
these factors, product development and commercialization risks, the
uncertainty of whether the results of clinical trials will be
predictive of results in later stages of product development, the
risk of delays or failure to obtain or maintain regulatory
approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual
property rights in product candidates and the ability to defend and
enforce such intellectual property rights, the risk of failure of
the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform
as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical
trials or significant issues regarding the adequacy of clinical
trial designs or the execution of clinical trials, and the timing
of expected filings with the regulatory authorities, MediciNova's
collaborations with third parties, the availability of funds to
complete product development plans and MediciNova's ability to
obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties
described in MediciNova's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K for the year
ended December 31, 2020 and its subsequent periodic reports on Form
10-Q and current reports on Form 8-K. Undue reliance should not be
placed on these forward-looking statements, which speak only as of
the date hereof. MediciNova disclaims any intent or obligation to
revise or update these forward-looking statements.
INVESTOR CONTACT:Geoff O'BrienVice PresidentMediciNova,
Inc.info@medicinova.com
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Sep 2023 to Sep 2024